Skip to main content
Erschienen in: Infection 4/2014

01.08.2014 | Case Report

Histopathological evidence of invasive gastric mucormycosis after transarterial chemoembolization and liver transplantation

verfasst von: P. Kaiser, E. M. Maggio, T. Pfammatter, B. Misselwitz, S. Flury, P. M. Schneider, P. Dutkowski, S. Breitenstein, B. Müllhaupt, P. A. Clavien, N. J. Mueller

Erschienen in: Infection | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

We describe a case of a 62-year-old diabetic woman with hepatocellular carcinoma due to chronic hepatitis B virus infection. Two weeks after orthotopic liver transplantation, endoscopy for massive upper gastrointestinal bleeding revealed a large necrotic area in the gastric fundus. The patient underwent emergency resection. Histopathologically, angioinvasive mold infection compatible with mucormycosis was diagnosed in a large area of necrosis, mimicking an atypically localized gastric ulcer. Foreign bodies originating from transarterial chemoembolization (TACE) performed 7 and 8 months earlier and 40 days before transplantation were identified in the submucosal tissue. The patient was treated with liposomal amphotericin B (LAB) for 5 weeks, followed by 7 weeks of posaconazole. Follow-up biopsies after 1 and 5 months confirmed successful treatment. Review of the radiological images of the TACE procedure showed that some of the TACE material had been diverted to the stomach via an accessory gastric branch originating from the left hepatic artery. TACE agents may be associated with chronic, refractory gastroduodenal ulcers. We hypothesize that the ischemic lesion was first colonized with presumed Mucorales mold and invasive growth was promoted by the posttransplantation immunosuppression. Careful exploration of extrahepatic collaterals during TACE may prevent this complication.
Literatur
1.
Zurück zum Zitat Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012;54:S8–15.PubMedCentralPubMedCrossRef Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012;54:S8–15.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.PubMedCrossRef Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.PubMedCrossRef
3.
Zurück zum Zitat Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54:S23–34.PubMedCrossRef Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54:S23–34.PubMedCrossRef
4.
Zurück zum Zitat Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44:335–42.PubMedCrossRef Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44:335–42.PubMedCrossRef
5.
Zurück zum Zitat Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17:1855–64.PubMedCentralPubMedCrossRef Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17:1855–64.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Spellberg B. Gastrointestinal mucormycosis: an evolving disease. Gastroenterol Hepatol (N Y). 2012;8:140–2. Spellberg B. Gastrointestinal mucormycosis: an evolving disease. Gastroenterol Hepatol (N Y). 2012;8:140–2.
7.
Zurück zum Zitat Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case–control study to assess risks for disease and outcome. J Infect Dis. 2009;200:1002–11.PubMedCrossRef Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case–control study to assess risks for disease and outcome. J Infect Dis. 2009;200:1002–11.PubMedCrossRef
8.
Zurück zum Zitat Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11.PubMedCrossRef Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11.PubMedCrossRef
9.
Zurück zum Zitat Thomson SR, Bade PG, Taams M, et al. Gastrointestinal mucormycosis. Br J Surg. 1991;78:952–4.PubMedCrossRef Thomson SR, Bade PG, Taams M, et al. Gastrointestinal mucormycosis. Br J Surg. 1991;78:952–4.PubMedCrossRef
10.
Zurück zum Zitat Leung TK, Lee CM, Chen HC. Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J Gastroenterol. 2005;11:1554–7.PubMed Leung TK, Lee CM, Chen HC. Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J Gastroenterol. 2005;11:1554–7.PubMed
11.
Zurück zum Zitat Ingraham CR, Johnson GE, Nair AV, et al. Nontarget embolization complicating transarterial chemoembolization in a patient with hepatocellular carcinoma. Semin Intervent Radiol. 2011;28:202–6.PubMedCentralPubMedCrossRef Ingraham CR, Johnson GE, Nair AV, et al. Nontarget embolization complicating transarterial chemoembolization in a patient with hepatocellular carcinoma. Semin Intervent Radiol. 2011;28:202–6.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–9.PubMedCrossRef Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–9.PubMedCrossRef
13.
Zurück zum Zitat Ibrahim AS, Avanessian V, Spellberg B, et al. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother. 2003;47:3343–4.PubMedCentralPubMedCrossRef Ibrahim AS, Avanessian V, Spellberg B, et al. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother. 2003;47:3343–4.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–67.PubMedCrossRef Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–67.PubMedCrossRef
15.
Zurück zum Zitat Lewis RE, Lortholary O, Spellberg B, et al. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis. 2012;54:S67–72.PubMedCrossRef Lewis RE, Lortholary O, Spellberg B, et al. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis. 2012;54:S67–72.PubMedCrossRef
16.
Zurück zum Zitat Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289–97.PubMedCrossRef Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289–97.PubMedCrossRef
17.
Zurück zum Zitat Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98:492–504.PubMedCentralPubMedCrossRef Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98:492–504.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clin Microbiol Infect. 2014 [Epub ahead of print]. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clin Microbiol Infect. 2014 [Epub ahead of print].
19.
Zurück zum Zitat Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMedCentralPubMedCrossRef Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMedCentralPubMedCrossRef
Metadaten
Titel
Histopathological evidence of invasive gastric mucormycosis after transarterial chemoembolization and liver transplantation
verfasst von
P. Kaiser
E. M. Maggio
T. Pfammatter
B. Misselwitz
S. Flury
P. M. Schneider
P. Dutkowski
S. Breitenstein
B. Müllhaupt
P. A. Clavien
N. J. Mueller
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 4/2014
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0603-7

Weitere Artikel der Ausgabe 4/2014

Infection 4/2014 Zur Ausgabe

Clinical and Epidemiological Study

Extra-pulmonary tuberculosis: a biomarker analysis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.